Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Provider Practices Regarding Prophylactic Anticoagulation in Children with Leukemia

Nicole Kucine, MD, Melanie Degliuomini, MD, Elizabeth Mauer, MS, Victoria Cooley, MS, Linda M Gerber, PhD, Suchitra Acharya, MD

Blood (2019) 134 (Supplement_1): 3412.

https://doi.org/10.1182/blood-2019-123084

Published: 2019

Journal Articles

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Blood (2019) 134 (Supplement_1): 1532.

https://doi.org/10.1182/blood-2019-131442

Published: 2019

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Cecile Tomowiak, MD, Kristell Desseaux, Stéphanie Poulain, MD PhD, Charles Herbaux, MD, Aurore Perrot, MD PhD, Beatrice Mahe, MD, Pierre Morel, MD, Olivier Tournilhac, Stephane Lepretre, MD, Thérèse Aurran, MD, Bruno Villemagne, MD, Olivier Casasnovas, MD, Delphine Nollet, Brigitte Dreyfus, MD, Sylvie Chevret, MD PhD, Veronique Leblond, MD PhD

Blood (2019) 134 (Supplement_1): 346.

https://doi.org/10.1182/blood-2019-122826

Published: 2019

Journal Articles

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 4016.

https://doi.org/10.1182/blood-2019-129212

Published: 2019

Journal Articles

Therapeutic Plasma Exchange in Pediatrics for Immunologic Disorders; Tolerated and Safe Process for Pediatric Life-Threatening Conditions

Blood (2019) 134 (Supplement_1): 4986.

https://doi.org/10.1182/blood-2019-122106

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Journal Articles

Clinical Implications of MYD88 and CXCR4 in Patients with Waldenström's Macroglobulinemia

Martina Divoka, Tomas Pika, MD PhD, Lenka Krupkova, Monika Orviska, Romana Janska, Jiri Minarik, MD PhD, Tomas Papajik, MD prof

Blood (2018) 132 (Supplement 1): 5314.

https://doi.org/10.1182/blood-2018-99-112855

Published: 2018

Journal Articles

Ophthalmic Manifestations of Chronic Myeloid Leukemia As Initial Presentation and Unmet Needs

Shehab Mohamed, MD, Abdulqadir Jeprel Nashwan, BSN, MSN, RN, CBT-HMS, Ahmed Qatami, Mohamed A Yassin, MBBS, MSc

Blood (2018) 132 (Supplement 1): 5454.

https://doi.org/10.1182/blood-2018-99-115731

Published: 2018

Journal Articles

Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model

Saurabh Zanwar, MBBS, Jithma Prasad Abeykoon, MD, Stephen M. Ansell, MD PhD, Angela Dispenzieri, MD, Morie A. Gertz, MD, David J Inwards, MD, Thomas E. Witzig, MD, Martha Q. Lacy, MD, Thomas M. Habermann, MD, David Dingli, MD PhD, Francis K. Buadi, MB, CHB, Ronald S. Go, MD, Wilson I Gonsalves, MD, Eli Muchtar, MD, Robert A. Kyle, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD, Prashant Kapoor, MD

Blood (2018) 132 (Supplement 1): 4152.

https://doi.org/10.1182/blood-2018-99-119849

Published: 2018

Journal Articles

Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia

Gilad Itchaki, Toni Dubeau, NP, Andrew Keezer, BS, Kirsten Meid, MPH, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2018-99-114254

Published: 2018

Journal Articles

Hyperviscosity syndrome in splenic marginal zone lymphoma

Raeye Daniel, Randall Y. Chan

Blood (2018) 132 (15): 1627.

https://doi.org/10.1182/blood-2018-07-863787

Published: 2018

Journal Articles

Acute hyperviscosity: syndromes and management

Morie A. Gertz

Blood (2018) 132 (13): 1379–1385.

https://doi.org/10.1182/blood-2018-06-846816

Published: 2018

Journal Articles

Predictors of Hyperviscosity Syndrome (HVS) in Waldenström Macroglobulinemia (WM)

Blood (2017) 130 (Supplement 1): 4022.

https://doi.org/10.1182/blood.V130.Suppl_1.4022.4022

Published: 2017

Journal Articles

Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound

Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Lian Xu, Zachary Hunter, PhD, Steven P Treon, MDPhDFRCP, Jorge J. Castillo, MD

Blood (2017) 130 (Supplement 1): 802.

https://doi.org/10.1182/blood.V130.Suppl_1.802.802

Published: 2017

Journal Articles

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Joshua Gustine, Kirsten Meid, MPH, Patricia Severns, NP, Toni Dubeau, NP, Nickolas Tsakmaklis, BA, Christopher Patterson, MAcc, Guang Yang, PhD, Xia Liu, MD, Maria Demos, BS, Amanda Kofides, BS, Jiaji Chen, BS, Manit Munshi, MS, Maria Luisa Guerrera, MD, Gloria Chan, MS, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MDPhDFRCP, Lian Xu

Blood (2017) 130 (Supplement 1): 5140.

https://doi.org/10.1182/blood.V130.Suppl_1.5140.5140

Published: 2017

Journal Articles

Natural History and Outcomes of Asymptomatic IgM Monoclonal Gammopathy

Efstathios Kastritis, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Alexandra Papathoma, Ioannis Panagiotidis, Magdalini Migkou, Despina Fotiou, Dimitrios C. Ziogas, Ioannis Ntanasis-Stathopoulos, Marilyn Spyropoulou-Vlachou, Anna Tasidou, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 1882.

https://doi.org/10.1182/blood.V130.Suppl_1.1882.1882

Published: 2017

Journal Articles

Red Cell Exchange: A Concise Review of Indications and Management

Elizabeth Biller, Yong Zhao, Lejla Music-Aplenc, MD, Mary Berg, MD, Lisa N Boggio, MD MS, Theresa Boyd, Kelley Capocelli, Deanna C Fang, Scott A Koepsell, MD, PhD, FCAP, Huy P. Pham, MD, M.P.H., Angela Treml, John Weiss, Geoffrey D. Wool, MD PhD, Beverly W Baron

Blood (2017) 130 (Supplement 1): 4800.

https://doi.org/10.1182/blood.V130.Suppl_1.4800.4800

Published: 2017

Journal Articles

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 1488.

https://doi.org/10.1182/blood.V130.Suppl_1.1488.1488

Published: 2017

NARROW

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Provider Practices Regarding Prophylactic Anticoagulation in Children with Leukemia

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Therapeutic Plasma Exchange in Pediatrics for Immunologic Disorders; Tolerated and Safe Process for Pediatric Life-Threatening Conditions

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Clinical Implications of MYD88 and CXCR4 in Patients with Waldenström's Macroglobulinemia

Ophthalmic Manifestations of Chronic Myeloid Leukemia As Initial Presentation and Unmet Needs

Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model

Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia

Hyperviscosity syndrome in splenic marginal zone lymphoma

Acute hyperviscosity: syndromes and management

Predictors of Hyperviscosity Syndrome (HVS) in Waldenström Macroglobulinemia (WM)

Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Natural History and Outcomes of Asymptomatic IgM Monoclonal Gammopathy

Red Cell Exchange: A Concise Review of Indications and Management

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only